Harrison

This research aims to evaluate the use of PET scans with two different radiotracers, FDG and FDHT, in men with progressive prostate cancer. The study focuses on whether these scans can better detect areas where the cancer may have spread in the body. It builds on earlier findings that changes in FDG uptake relate to cancer progression and treatment response, and now investigates FDHT, which targets the androgen receptor in prostate cancer. Participants will undergo PET scans using FDHT alone or both FDG and FDHT based on clinical questions. Scans will take place at baseline, 4 weeks, 12 weeks, and then every 12 weeks for up to one year, with a maximum of 8 scan sets per year and 40 over a lifetime unless otherwise directed. Some patients may have blood draws to study how FDHT moves through the body and may have an initial dynamic scan followed by a standard whole-body PET scan. During the study, researchers will assess where and how much FDHT accumulates in tumors, comparing these findings with other imaging like bone scans, CT, and MRI at baseline, 4 weeks, and 12 weeks. They will also monitor kinetics and metabolism of the tracer, changes over time, and correlations with disease markers and tissue analyses. The study involves repeated imaging and blood tests to better understand prostate cancer progression and response to treatment.

Researchers are evaluating the safety, efficacy, and optimal dosing of a combination of two investigational treatments, BNT323 trastuzumab pamirtecan and BNT327 pumitamig, in people with advanced breast cancer. This includes those with hormone receptor-positive or -negative, HER2-positive, HER2-low, HER2-ultralow, HER2-null breast cancer, or triple-negative breast cancer. The study is a Phase III multi-site, open-label trial with a focus on advanced breast cancer treatment options. The study has two parts. Part 1 involves dose escalation of BNT323 combined with BNT327 to determine the recommended Phase 2 dose using six different dose levels. Part 2, which begins after Part 1 completion, includes dose optimization and exploratory cohorts. Cohort 1 in Part 2 uses randomization into four treatment arms, including combination therapy at different doses and monotherapies of either BNT323 or BNT327. Other cohorts receive the recommended dose without randomization. Participants will undergo assessments including tumor scans and cardiac function tests, with monitoring for side effects and tumor response up to 36 months. Researchers will track dose-limiting toxicities and treatment-emergent adverse events during early treatment cycles and monitor objective response rates and disease control over time. Safety and efficacy data will be collected through scheduled visits and tumor assessments during and after treatment to evaluate the study drugs effects and tolerability.

Researchers are evaluating whether a high-fiber plant-based diet HFPBD can improve quality of life for people with clonal hematopoiesis CH. This diet mainly includes plant foods such as fruits, vegetables, nuts, beans, and whole grains. The study measures quality of life using questionnaires and surveys filled out by participants. Participants will be randomly assigned to one of two groups. One group will receive high-fiber plant-based meals delivered to their homes for 12 weeks and have regular phone or video calls with a dietitian every 2 weeks for the first 12 weeks, every 4 weeks from weeks 13 to 24, and every 8 weeks from weeks 25 to 52. The other group will receive usual care with phone calls every 4 weeks for the first 12 weeks and dietitian calls at weeks 13 and 53. During the study, participants will complete quality of life surveys using the EORTC QLQ C30 questionnaire. Assessments include phone or video visits with dietitians, dietary intake monitoring, and adherence to the assigned diet. The main outcome is improvement in quality of life within the first 12 weeks. The total study duration for participants is 52 weeks, with ongoing monitoring and support throughout this time.

Researchers are investigating whether a dietary intervention can influence treatment response and quality of life in people with newly diagnosed multiple myeloma undergoing standard induction chemotherapy with daratumumab or isatuximab, lenalidomide, bortezomib, and dexamethasone DRVd. The study aims to assess the effects of diet on quality of life, treatment response, and various disease, microbiome, and immune markers by having participants complete questionnaires and other evaluations. Participants are randomly assigned to one of two groups. One group receives usual care, which includes standard chemotherapy and phone calls every 4 weeks with study staff and a dietitian consultation at the end of chemotherapy. The other group receives an intervention with nutrition counseling and coaching, including biweekly dietitian calls for 12 weeks and high-fiber plant-based frozen meals shipped weekly for 12 weeks. Optional group sessions and text message reminders are also provided. Both groups complete dietary and quality of life surveys during the study. During the study, participants complete questionnaires measuring quality of life and dietary intake. Researchers will evaluate the rate of minimal residual disease negative complete response at one year and compare quality of life improvements between groups. Phone or video calls with dietitians and study staff support participant engagement. The study lasts through four 28-day chemotherapy cycles with follow-up assessments up to one year to monitor treatment and quality of life outcomes.

Researchers are evaluating whether telehealth music therapy can be a practical treatment for cognitive difficulties in adults who have survived blood cancers such as lymphoma, leukemia, or myeloma. The study also examines if music therapy and music education can help improve cognitive function as well as symptoms like anxiety, depression, and fatigue in this population. This pilot trial is exploring these effects in hematologic cancer survivors who experience cancer-related cognitive dysfunction. Participants will be assigned to one of three groups the experimental music therapy MT group, the therapist-attention music education TAME control group, or a wait-list control WLC group receiving usual care. Those in the MT and TAME groups will receive 12 weekly 60-minute sessions, with homework assignments between sessions to reinforce skills and concepts. The WLC group completes assessments during a 24-week wait period and can later choose to receive either the MT or TAME intervention. During the study, participants will complete assessments to measure the feasibility of telehealth music therapy, defined by completing at least 9 of the 12 sessions. Researchers will monitor cognitive function, mood symptoms, and fatigue. Participants must be able to complete study assessments independently and consent in English. The total study duration includes the intervention period and follow-up assessments to evaluate outcomes related to cancer-related cognitive dysfunction.

Researchers are studying patients with Stage I lung cancer who are undergoing planned pulmonary segmentectomy surgery. The study aims to understand the disease-free survival rates at 3 and 5 years after this surgery in people suitable for this procedure based on clinical staging. Patients with suspected non-small cell lung cancer are included, even if tissue diagnosis is not confirmed before surgery. Participants in this observational study complete questionnaires using the Patient-Reported Outcomes Measurement Information System PROMIS, which evaluates physical function, pain interference, and breathing difficulty. These questionnaires are completed before surgery, between 2 to 4 weeks after surgery, and again 6 months after surgery. The study collects data through this web-based platform developed by the National Institutes of Health. During the study, participants are asked to fill out surveys at specified times to assess their health and symptoms. Researchers will track disease-free survival over 3 and 5 years after surgery to evaluate outcomes. Participation involves completing questionnaires and follow-up over several years, with no investigational treatment being administered. The total study completion is expected by May 2029.

Researchers are collecting detailed information in a registry to better understand various types of mature T-cell and natural killer NK-cell lymphomas. This observational study aims to improve knowledge about these rare blood cancers by creating a comprehensive database that includes clinical information and tumor samples from participants. The study is sponsored by Memorial Sloan Kettering Cancer Center and focuses on multiple specific T-cell lymphoma subtypes as defined by recognized classification guidelines. Participants with confirmed mature T-cell or NK-cell lymphoma may choose to provide optional blood and nail samples for future research and biobanking. The study does not involve experimental treatments but gathers data prospectively from individuals meeting strict diagnostic criteria, including those receiving systemic therapy for certain cutaneous lymphoma types. This approach supports long-term data collection rather than testing new therapies. During the study, participants will have clinical data and tumor specimens collected and recorded. Researchers will track the number of participants contributing to the T-cell Lymphoma Master Repository over a 10-year period. The study involves ongoing follow-up to measure disease status and treatment response, with no direct intervention required. Participation helps build a resource to advance future research and understanding of these lymphomas.

Researchers are creating a registry to study people with early changes in the stomach lining that may lead to gastric cancer. This includes those with gastric atrophy, intestinal metaplasia, and dysplasia. The study also enrolls healthy individuals and people with gastric cancer to compare baseline characteristics and better understand risk factors for disease progression. Participants fall into three groups those with specific stomach lesions, healthy controls, and people with gastric cancer. The study collects information through questionnaires about clinical history, environmental exposures, lifestyle, and diet. This observational study does not involve any treatment but gathers health data to support future research. Participants will complete questionnaires and provide health information over a period that may last up to 10 years. The main goal is to build a detailed participant registry. Researchers will monitor and analyze the collected data to identify factors related to the progression of stomach lesions to cancer. Participation involves regular data collection but no active treatment, with safety and privacy monitored throughout the study.

Researchers are studying how butyrate levels in stool change after following a plant-based diet for at least 12 weeks in people with monoclonal gammopathy of undetermined significance MGUS or smoldering multiple myeloma SMM. The study compares the effects of a plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo on these butyrate levels. This randomized, placebo-controlled trial is conducted by Memorial Sloan Kettering Cancer Center to explore nutritional interventions in these conditions. Participants will be assigned to one of three groups a plant-based diet group receiving two premade meals daily for 12 weeks a supplement group taking algae omega-3 and curcumin supplements twice daily for 52 weeks or a placebo group receiving inactive supplements twice daily for 25 weeks. The plant-based diet includes low glycemic meals with legumes, vegetables, whole grains, and plant fats, coupled with dietary education and counseling every 4 weeks. During the study, participants will be monitored through stool samples to assess microbiome diversity at 12 weeks. They will receive ongoing dietary support and have access to study staff for questions. The study lasts up to 52 weeks depending on the group, with regular assessments to track adherence, safety, and changes in butyrate levels. The research aims to understand how diet and supplements affect gut health in MGUS and SMM patients.

Researchers are evaluating if combining propranolol and etodolac with mind-body resilience training MBRT and music therapy can help women experiencing physiological stress around the time of primary debulking surgery PDS or interval debulking surgery IDS for ovarian cancer. The study compares this combined approach to the standard care, which does not include specific interventions to reduce stress. This trial is designed as a prospective randomized pilot study led by Memorial Sloan Kettering Cancer Center, focusing on stress prevention during surgery for advanced ovarian and related cancers. Participants in the intervention group will receive a combination of mind-body resilience training, music therapy, propranolol, and etodolac both before and after surgery. Propranolol is given at 20 mg twice daily for 21 days, then 10 mg twice daily for 3 days after surgery postoperative days 14-16. Etodolac is administered at 400 mg twice daily for 21 days. Psychological interventions may also be provided postoperatively if needed between days 1 to 7 after surgery. The comparison group will receive usual care without these specific stress-reduction interventions. During the study, participants will be monitored for adherence, including completing over 80% of the bundled interventions by 21 days after surgery. Researchers will assess the effectiveness of the interventions in reducing physiological stress around the time of surgery. Participation involves scheduled surgeries, medication administration, behavioral therapy sessions, and possible psychological support. The total study duration extends up to the primary completion date in June 2027, with follow-up focused on intervention adherence and stress response outcomes.